Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Organisation › Details

Silence Therapeutics plc (AIM: SLN)

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. The company possesses multiple proprietary short interfering RNA (siRNA) delivery technology platforms including AtuPLEX™, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. Additionally, the company has a platform of novel siRNA molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including reduced cytokine induction and decreased manufacturing costs. Silence's unique RNAi assets also include structural features for a next generation of RNAi molecules and additional proprietary siRNA sequences against more than 50 highly valued oncology and other disease targets. The Company's lead internal drug candidate is Atu027, a liposomal AtuRNAi formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutics in the area of oncology. Silence is currently conducting an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid tumors involving single, as well as, repeated intravenous administration. The study is expected to be completed in the second half of 2011. The Company's RNAi therapeutic platform has received key validation through multiple partnerships with pharmaceutical companies including AstraZeneca, Dainippon Sumitomo, Pfizer, and Quark. Silence is actively pursuing the establishment of additional partnerships. *

 

Period Start 2007-04-26 renamed
  Group Silence Therapeutics (Group)
  Predecessor SR Pharma plc (AIM: SPA.L)
Product Industry siRNA therapeutic
Persons Person Solomon, David Horn (Silence Therapeutics 201807– CEO before Zealand Pharma + Bionor Pharma + Akari Therapeutics)
  Person 2 Ellam, David (Juvenescence 201904– CFO before Silence Therapeutics + BioMarin + Plethora Solutions + Ark Therapeutics)
     
Region Region London, Greater London
  Country United Kingdom (GB)
  Street 72 Hammersmith Road
  City W14 8TH London
  Tel +44-20-3457-6900
    Address record changed: 2019-08-20
     
Basic data Employees B: 11 to 50 (2018-12-31)
  Currency GBP
  Profit -18,411,000 (2018-12-31)
  Cash 21,494,000 (2018-12-31)
     
    * Document for �About Section�: Silence Therapeutics plc. (8/1/11). "Press Release: Group Reorganisation and Board Changes". London.
     
   
Record changed: 2019-09-23

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Silence Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top